[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fO-MI0BoTJqBOy9ZYsLtIrWs37r4jaBUEyhvviVS9Y8Q":8,"$fiorwm2O9XXTwtw2NHSo6iSROYQBmWiuhzPvKQKyHTIM":55,"$fZ7K_0lujhln45wJABcvnvS2VDnHIOM7IRiKr8duaWjw":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68632,863402,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//0Rvlsm1tdkSbq5L99bjhchaojzwJ5kCw.png","华晓萍","浙江大学医学院附属妇产科医院","妇科","主治医师",94,0,"🩺卵巢癌IIIC期高级别浆液性癌：常用药物安全用药指南","","https://ystcdn.venuertc.com/venue/AI/6695369d-0baf-48b9-94a8-9e2325febed8.jpg","\u003Cdiv class=\"ovarian-drug-guide-wrap\">\n  \u003Ch1 id=\"material_title\" class=\"ovarian-drug-guide-title\">\n    🩺卵巢癌IIIC期高级别浆液性癌：常用药物安全用药指南\n  \u003C/h1>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-subtitle-bg\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">引言：绕不开的药品安全细节\u003C/h2>\n      \u003Cp class=\"ovarian-drug-guide-text\">\n        说到用于卵巢癌治疗的药品，比如贝伐珠单抗注射液、奥拉帕利、谷胱甘肽注射液、兰索拉唑注射液、肝素钠封管液等，它们各自有着独特的使用要求和风险。安全用药不仅关乎治疗效果，更是避免不良反应和后续麻烦的关键。这篇指南将用7个主题，详细讲明相关药品的正确应用方式、相互作用和潜在副作用，让每位使用者都能做到心中有数、用药不误。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-1\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">01 贝伐珠单抗注射液：用药关键要点\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药品成分与作用机制\u003C/span>\u003Cbr>\n          贝伐珠单抗是一种重组人源化单克隆抗体，主要通过阻断血管内皮生长因子（VEGF），从而抑制新生血管生成，减少肿瘤周围血供。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-data\">（Ferrara et al., Nature Reviews Cancer, 2004）\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">具体用法用量\u003C/span>\u003Cbr>\n          贝伐珠单抗通常以静脉滴注给药，一般建议每三周一次，剂量需根据实际体重计算。首次滴注速度应较慢，观察是否出现反应，后续可适当提高速度。药液不得与葡萄糖溶液混合。\u003Cbr>\n          正确做法：每次输液前、后应检查静脉通道是否通畅，避免液体外渗。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-tip\">💡多位患者输注后需监测血压和蛋白尿。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">用药注意事项与禁忌\u003C/span>\u003Cbr>\n          禁忌：对贝伐珠单抗或者其辅料过敏者禁用。未愈合伤口、近期有手术史者不推荐使用。孕妇、哺乳期女性不可使用。\u003Cbr>\n          需要注意：应用于维持治疗时，如遇延迟或换药，应重新评估血压、肾功能。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药物相互作用\u003C/span>\u003Cbr>\n          贝伐珠单抗与含铂类化疗药物合用时可增强疗效，但同时不良反应发生率升高。合用抗高血压药物需密切观察。\u003Cbr>\n          正确做法：同周期如需联合其它静脉注射药，应分隔不同输液管或先后输注，避免相互反应。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-data\">临床数据显示，联合化疗期间蛋白尿发生率约为15%。（Burger et al., JCO, 2011）\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">常见不良反应及处理\u003C/span>\u003Cbr>\n          高血压、蛋白尿、出血倾向是最常见副作用。长时间使用有少数患者出现胃肠穿孔，极罕见。\u003Cbr>\n          正确做法：用药期间应定期监测血压、尿蛋白。发现异常应及时相应处理或暂停用药。出现严重不良事件时务必及时就医。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">储存与保存\u003C/span>\u003Cbr>\n          贝伐珠单抗必须冷藏保存（2-8℃），避免冷冻或高温。使用前检查药品外观，无变色或沉淀方可使用。\u003Cbr>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"ovarian-drug-guide-case\">\n        \u003Cspan class=\"ovarian-drug-guide-list-title\">药品实际用药案例：\u003C/span>\n        本病例患者因维持治疗，目前按周期继续贝伐珠单抗注射液输注。因近期延迟8天，需要重新评估肾功能和血压，确保用药安全。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-2\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">02 奥拉帕利：口服维持用药细节\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">成分与作用机制\u003C/span>\u003Cbr>\n          奥拉帕利为PARP抑制剂，通过抑制多腺苷酸二磷酸核糖聚合酶（PARP），影响DNA修复过程，增强肿瘤细胞死亡。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-data\">(Ledermann et al., The Lancet Oncology, 2014)\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">用法用量\u003C/span>\u003Cbr>\n          奥拉帕利以片剂形式口服，一般每日两次，推荐在饭前或饭后服用均可。吞服时应保证足量饮水，不应压碎或嚼碎药片。\u003Cbr>\n          正确做法：若漏服一次，尽快补服。若已接近下次剂量，不需要加倍补服。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">相互作用\u003C/span>\u003Cbr>\n          禁止与强效CYP3A抑制剂（如酮康唑）同时服用，易导致血药浓度升高。\u003Cbr>\n          需谨慎：合用圣约翰草或其他诱导CYP3A药物时，奥拉帕利效果减弱。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">特殊人群剂量调整\u003C/span>\u003Cbr>\n          肾功能不全患者需要调整药物剂量。孕妇及哺乳期妇女不得服用。\u003Cbr>\n          老年人通常无需调整剂量，但应定期检测血常规。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">不良反应与处理\u003C/span>\u003Cbr>\n          最常见：恶心、疲劳、贫血、腹泻。数据显示，超过30%的患者可能出现轻度消化道不适。\u003Cbr>\n          处理方法：适度调整饮食，多喝水。贫血明显时须复查。如出现严重反应，及时咨询医生。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-tip\">🍂实际服用后如出现无法缓解的胃肠道反应，建议短暂停药并寻求医生指导。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">储存方法\u003C/span>\u003Cbr>\n          奥拉帕利需放置在25℃以下干燥环境，避免高温和潮湿。开封后严禁用手接触药片表面，以免影响药效。\u003Cbr>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"ovarian-drug-guide-case\">\n        \u003Cspan class=\"ovarian-drug-guide-list-title\">药品实际用药案例：\u003C/span>\n        临床上一名HRD阳性患者口服奥拉帕利作为维持治疗，需常规每月复查血象，监测贫血情况。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-3\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">03 谷胱甘肽注射液：辅助用药与注意事项\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药品成分与作用机制\u003C/span>\u003Cbr>\n          谷胱甘肽是三肽类抗氧化剂，用于提升细胞抗氧化能力，在化疗期间可辅助减轻某些不良反应。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-data\">(Pizzorno, Integrative Medicine, 2014)\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">用法用量\u003C/span>\u003Cbr>\n          注射液需静脉注射，通常根据体重及医生建议调整剂量，每次用药前确保药液澄清无异物。\u003Cbr>\n          正确做法：严格遵医嘱，不得随意更改剂量。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">禁忌和特殊群体\u003C/span>\u003Cbr>\n          禁忌：对谷胱甘肽及任何成分过敏者不得使用。孕妇及哺乳期妇女慎用。儿童用药需权衡利弊。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">常见不良反应\u003C/span>\u003Cbr>\n          可出现轻度注射部位红肿或过敏反应。极罕见情况下发生呼吸困难。\u003Cbr>\n          正确做法：若出现明显不适，立即停止用药并求助医生。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">储存方法\u003C/span>\u003Cbr>\n          需冷藏保存（2-8℃），不可冷冻。每次使用前检验药液外观，确保无异常。\u003Cbr>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"ovarian-drug-guide-case\">\n        \u003Cspan class=\"ovarian-drug-guide-list-title\">药品实际用药案例：\u003C/span>\n        多数患者在化疗期间用于辅助保护，建议每次使用前充分沟通药物过敏史。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-4\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">04 兰索拉唑注射液：抑酸药，正确使用方法\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药品成分与作用机制\u003C/span>\u003Cbr>\n          兰索拉唑属于质子泵抑制剂，通过抑制胃壁细胞氢钾ATP酶，减少胃酸分泌。常用于缓解胃肠道刺激加剧时作为辅助用药。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-data\">(Richter, Therapeutic Advances in Gastroenterology, 2013)\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">用法用量\u003C/span>\u003Cbr>\n          仅限静脉给药，不可口服或肌注。注射液需现配现用，推荐滴注时间不少于30分钟。\u003Cbr>\n          正确做法：稀释后尽快使用，不得存放超过2小时。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药物相互作用\u003C/span>\u003Cbr>\n          长期合用抗凝药（如华法林）时需动态监测凝血功能。不得与奥拉帕利同输一管。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">不良反应及处理\u003C/span>\u003Cbr>\n          注射部位偶见红肿、过敏。长期使用可能影响维生素B12吸收。\u003Cbr>\n          正确做法：如发现不良反应，及时调整用药。长期用药者建议补充膳食维生素。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">储存方法\u003C/span>\u003Cbr>\n          原液需干燥避光保存（室温15-25℃），配制后不得存放。\u003Cbr>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-5\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">05 肝素钠封管液：用于维持静脉通路\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药品成分与作用机制\u003C/span>\u003Cbr>\n          肝素为抗凝剂，通过增强抗凝血酶III活性阻止血栓形成，主要用于维持静脉导管通畅。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-data\">(Chai-Adisaksopha et al., Thrombosis Research, 2014)\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">用法用量\u003C/span>\u003Cbr>\n          用于导管封管时，严格按照医生开具的滴度和用量，直接注入静脉导管，不得与其它药物混合。\u003Cbr>\n          正确做法：注射完毕后，需抽出残液以防药物进入体内。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">禁忌与注意事项\u003C/span>\u003Cbr>\n          对肝素、猪源成分过敏者禁用。已知出血倾向、严重肝肾功能异常者不得用。\u003Cbr>\n          用药期间如有局部红肿、渗血应立即停用并报告医生。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">药物相互作用\u003C/span>\u003Cbr>\n          不应与口服抗凝剂（如华法林）同步使用，可导致协同出血风险增高。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">储存要求\u003C/span>\u003Cbr>\n          干燥阴凉处保存，避免高温。每次开封务必核对有效期和批次。\u003Cbr>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-6\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">06 实用经验与用药管理技巧\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">漏服与过量应对\u003C/span>\u003Cbr>\n          漏服奥拉帕利：如仅漏一顿，尽快补服，勿双倍剂量。过量服用或异常反应时，立即联系医生处理。\u003Cbr>\n          漏用贝伐珠单抗则需重新评估副作用风险和重新排班。\u003Cbr>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">合理组合与监测\u003C/span>\u003Cbr>\n          合并多种药品时，应根据医嘱逐一核对用药顺序和间隔，不可自行调整。\u003Cbr>\n          建议定期复查肾功能、血压、血象、肝酶水平。每月记录用药历程与反应，便于医生优化方案。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-tip\">📑规律监测可减少用药风险，提高长期用药安全性。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovarian-drug-guide-list-title\">患者实际管理教训\u003C/span>\u003Cbr>\n          某位患者因延迟输注贝伐珠单抗8天，重新评估肝肾功能及血压，有效预防了潜在风险。\u003Cbr>\n          临床用奥拉帕利联合化疗，须监测贫血和肾功能。出现用药不良反应后及时处理，可以避免后续问题。\u003Cbr>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-7\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">07 综合总结与用药安全提醒\u003C/h2>\n      \u003Cdiv class=\"ovarian-drug-guide-summary\">\n        \u003Cp>\n          卵巢癌治疗所涉及的贝伐珠单抗、奥拉帕利、谷胱甘肽、兰索拉唑、肝素钠等药品，各有自身关键注意点。务必按医嘱规范操作，不擅自加减剂量，严控联合用药风险。实际用药过程中，监测血压、肾功能、血象是提高安全性的基础。必要时及时就医，科学处理不良反应是保障治疗效果的核心。\u003Cbr>\n          \u003Cspan class=\"ovarian-drug-guide-tip\">🔔尤其个别药品如贝伐珠单抗、奥拉帕利，需高度关注高血压、蛋白尿及消化道反应。\u003C/span>\n        \u003C/p>\n        \u003Cp>\n          合理记录用药历程、主动配合复查，是优效、安全用药的关键。切记，安全第一，切莫轻视每一项细节。\u003Cbr>\n          如遇不良反应、疑问，务必及时向专业医生咨询。\n        \u003C/p>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \u003Csection class=\"ovarian-drug-guide-section\">\n    \u003Cdiv class=\"ovarian-drug-guide-bg-ref\">\n      \u003Ch2 class=\"ovarian-drug-guide-subtitle\">参考文献\u003C/h2>\n      \u003Cul class=\"ovarian-drug-guide-ref\">\n        \u003Cli>\n          Ferrara, N., Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. \u003Cem>Nature Reviews Cancer\u003C/em>, 5(8), 577-586.\n        \u003C/li>\n        \u003Cli>\n          Burger, R. A., Brady, M. F., Bookman, M. A., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. \u003Cem>Journal of Clinical Oncology\u003C/em>, 29(1), 33-38.\n        \u003C/li>\n        \u003Cli>\n          Ledermann, J., Harter, P., Gourley, C., et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a phase 2 trial. \u003Cem>The Lancet Oncology\u003C/em>, 15(8), 852-861.\n        \u003C/li>\n        \u003Cli>\n          Pizzorno, J. (2014). Glutathione!. \u003Cem>Integrative Medicine: A Clinician's Journal\u003C/em>, 13(1), 8-12.\n        \u003C/li>\n        \u003Cli>\n          Richter, J. E. (2013). Review article: the management of heartburn in pregnancy. \u003Cem>Therapeutic Advances in Gastroenterology\u003C/em>, 6(4): 255–268.\n        \u003C/li>\n        \u003Cli>\n          Chai-Adisaksopha, C., Hillis, C., Chan, N., et al. (2014). The efficacy and safety of anticoagulant prophylaxis using low molecular weight heparin and unfractionated heparin for prevention of venous thromboembolism in non-surgical hospitalized patients. \u003Cem>Thrombosis Research\u003C/em>, 133(1), 5-11.\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.ovarian-drug-guide-wrap {\n  max-width: 900px;\n  margin: 36px auto;\n  background: #faf8fd;\n  border-radius: 20px;\n  padding: 30px 30px 40px 30px;\n  box-shadow: 0 6px 30px rgba(101,49,175,0.07);\n  font-family: \"Microsoft YaHei\", \"Helvetica Neue\", Arial, sans-serif;\n  color: #322357;\n  font-size: 18px;\n}\n\n.ovarian-drug-guide-title {\n  font-size: 34px;\n  color: #613cb9;\n  margin-bottom: 44px;\n  letter-spacing: 1px;\n  text-align: center;\n  font-weight: bold;\n}\n\n.ovarian-drug-guide-section {\n  margin-top: 18px;\n  margin-bottom: 38px;\n}\n\n.ovarian-drug-guide-subtitle-bg {\n  background: linear-gradient(90deg, #f3f9fa 94%, #f3f1fa 100%);\n  padding: 22px 24px 10px 24px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-1 {\n  background: linear-gradient(100deg, #edf7fa 75%, #eaebf8 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-2 {\n  background: linear-gradient(130deg, #fef2ff 60%, #f6fdfb 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-3 {\n  background: linear-gradient(101deg, #f7fff8 75%, #eeebfa 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-4 {\n  background: linear-gradient(90deg, #f6f7fa 80%, #fbf2ff 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-5 {\n  background: linear-gradient(120deg, #eef6ff 65%, #f8f7fc 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-6 {\n  background: linear-gradient(140deg, #f3f6fa 70%, #f9f2f8 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n.ovarian-drug-guide-bg-7 {\n  background: linear-gradient(135deg, #fcfaf7 90%, #f1f4fa 100%);\n  padding: 18px 22px 10px 22px;\n  border-radius: 12px;\n}\n\n.ovarian-drug-guide-bg-ref {\n  background: linear-gradient(92deg, #f2f7fb 88%, #f9f1f9 100%);\n  padding: 18px 22px 18px 22px;\n  border-radius: 12px;\n}\n\n.ovarian-drug-guide-subtitle {\n  font-size: 26px;\n  color: #6244cc;\n  margin-bottom: 18px;\n  font-weight: bold;\n  letter-spacing: 1px;\n}\n\n.ovarian-drug-guide-text {\n  font-size: 18px;\n  color: #51497e;\n  line-height: 1.8;\n}\n\n.ovarian-drug-guide-list {\n  margin-top: 8px;\n  margin-left: 0;\n  padding-left: 20px;\n  list-style: disc inside;\n  color: #343a46;\n  font-size: 18px;\n}\n.ovarian-drug-guide-list-title {\n  font-weight: bold;\n  color: #694aec;\n  font-size: 19px;\n}\n\n.ovarian-drug-guide-case {\n  background: #f5f5fc;\n  border-left: 4px solid #8871df;\n  margin-top: 14px;\n  margin-bottom: 4px;\n  padding: 10px 18px;\n  border-radius: 9px;\n  color: #5e509e;\n  font-size: 17px;\n}\n\n.ovarian-drug-guide-tip {\n  display: inline-block;\n  color: #7a47be;\n  background: #edeaff;\n  border-radius: 4px;\n  padding: 2px 8px;\n  margin: 5px 0 5px 0;\n  font-size: 17px;\n}\n\n.ovarian-drug-guide-data {\n  color: #3496b7;\n  font-size: 15px;\n  margin-left: 6px;\n  font-style: italic;\n  background: #e7f6ff;\n  border-radius: 3px;\n  padding: 1px 6px;\n  display: inline-block;\n}\n\n.ovarian-drug-guide-summary {\n  font-size: 17px;\n  color: #34515b;\n  line-height: 1.8;\n  margin-top: 6px;\n  margin-bottom: 3px;\n}\n\n.ovarian-drug-guide-ref {\n  font-size: 16px;\n  color: #60677b;\n  margin-top: 14px;\n  margin-bottom: 4px;\n  padding-left: 18px;\n}\n.ovarian-drug-guide-ref li {\n  margin-bottom: 6px;\n  line-height: 1.7;\n}\n\n@media (max-width: 600px) {\n  .ovarian-drug-guide-wrap {\n    padding: 10px 5px 24px 5px;\n    border-radius: 8px;\n  }\n  .ovarian-drug-guide-title {\n    font-size: 25px;\n    margin-bottom: 20px;\n  }\n  .ovarian-drug-guide-subtitle {\n    font-size: 19px;\n  }\n  .ovarian-drug-guide-list-title {\n    font-size: 16px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"ovarian-drug-guide-wrap\">\n  \u003Ch1 id=\"material_title\" class=\"ovarian-drug-guide-title\">\n  ",512,"2025-10-28 00:17:22","卵巢癌, 贝伐珠单抗, 奥拉帕利, 药物安全, 不良反应指南","本文为卵巢癌患者提供贝伐珠单抗、奥拉帕利等药物的安全使用指南，确保高效治疗体验，降低不良反应风险。","2025-11-04 10:46:48",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]